BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Brandner S, Jaunmuktane Z. Prion disease: experimental models and reality. Acta Neuropathol 2017;133:197-222. [PMID: 28084518 DOI: 10.1007/s00401-017-1670-5] [Cited by in Crossref: 45] [Cited by in F6Publishing: 47] [Article Influence: 7.5] [Reference Citation Analysis]
Number Citing Articles
1 Ray A, Bonorden MJL, Pandit R, Nkhata KJ, Bishayee A. Infections and immunity: associations with obesity and related metabolic disorders. J Pathol Transl Med 2023;57:28-42. [PMID: 36647284 DOI: 10.4132/jptm.2022.11.14] [Reference Citation Analysis]
2 Staderini M, Vanni S, Baldeschi AC, Giachin G, Zattoni M, Celauro L, Ferracin C, Bistaffa E, Moda F, Pérez DI, Martínez A, Martín MA, Martín-cámara O, Cores Á, Bianchini G, Kammerer R, Menéndez JC, Legname G, Bolognesi ML. Bifunctional carbazole derivatives for simultaneous therapy and fluorescence imaging in prion disease murine cell models. European Journal of Medicinal Chemistry 2022. [DOI: 10.1016/j.ejmech.2022.114923] [Reference Citation Analysis]
3 Jaunmuktane Z, Brandner S. Transmissible human proteopathies: an expanding field. Diagnostic Histopathology 2022;28:417-423. [DOI: 10.1016/j.mpdhp.2022.07.002] [Reference Citation Analysis]
4 Mortberg MA, Minikel EV, Vallabh SM. Analysis of non-human primate models for evaluating prion disease therapeutic efficacy. PLoS Pathog 2022;18:e1010728. [DOI: 10.1371/journal.ppat.1010728] [Reference Citation Analysis]
5 Mortberg MA, Minikel EV, Vallabh SM. Analysis of non-human primate models for evaluating prion disease therapeutic efficacy.. [DOI: 10.1101/2022.03.22.485331] [Reference Citation Analysis]
6 Cazzaniga FA, Bistaffa E, De Luca CMG, Portaleone SM, Catania M, Redaelli V, Tramacere I, Bufano G, Rossi M, Caroppo P, Giovagnoli AR, Tiraboschi P, Di Fede G, Eleopra R, Devigili G, Elia AE, Cilia R, Fiorini M, Bongianni M, Salzano G, Celauro L, Quarta FG, Mammana A, Legname G, Tagliavini F, Parchi P, Zanusso G, Giaccone G, Moda F. PMCA-Based Detection of Prions in the Olfactory Mucosa of Patients With Sporadic Creutzfeldt–Jakob Disease. Front Aging Neurosci 2022;14:848991. [DOI: 10.3389/fnagi.2022.848991] [Reference Citation Analysis]
7 Thapa S, Marrero Winkens C, Tahir W, Arifin MI, Gilch S, Schatzl HM. Gene-Edited Cell Models to Study Chronic Wasting Disease. Viruses 2022;14:609. [DOI: 10.3390/v14030609] [Reference Citation Analysis]
8 Muronetz VI, Kudryavtseva SS, Leisi EV, Kurochkina LP, Barinova KV, Schmalhausen EV. Regulation by Different Types of Chaperones of Amyloid Transformation of Proteins Involved in the Development of Neurodegenerative Diseases. Int J Mol Sci 2022;23:2747. [PMID: 35269889 DOI: 10.3390/ijms23052747] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Shafiei G, Bazinet V, Dadar M, Manera AL, Collins DL, Dagher A, Borroni B, Sanchez-Valle R, Moreno F, Laforce R, Graff C, Synofzik M, Galimberti D, Rowe JB, Masellis M, Tartaglia MC, Finger E, Vandenberghe R, de Mendonça A, Tagliavini F, Santana I, Butler C, Gerhard A, Danek A, Levin J, Otto M, Sorbi S, Jiskoot LC, Seelaar H, van Swieten JC, Rohrer JD, Misic B, Ducharme S; Frontotemporal Lobar Degeneration Neuroimaging Initiative (FTLDNI), GENetic Frontotemporal dementia Initiative (GENFI). Network structure and transcriptomic vulnerability shape atrophy in frontotemporal dementia. Brain 2023;146:321-36. [PMID: 35188955 DOI: 10.1093/brain/awac069] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
10 Schwenke KA, Wälzlein JH, Bauer A, Thomzig A, Beekes M. Primary glia cells from bank vole propagate multiple rodent-adapted scrapie prions. Sci Rep 2022;12:2190. [PMID: 35140295 DOI: 10.1038/s41598-022-06198-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
11 Bujdoso R, Smith A, Fleck O, Spiropoulos J, Andréoletti O, Thackray AM. Prion disease modelled in Drosophila. Cell Tissue Res. [DOI: 10.1007/s00441-022-03586-0] [Reference Citation Analysis]
12 Walters RO, Haigh CL. Organoids for modeling prion diseases. Cell Tissue Res 2022. [PMID: 35088182 DOI: 10.1007/s00441-022-03589-x] [Reference Citation Analysis]
13 Nihat A, Mok TH, Odd H, Thompson AGB, Caine D, McNiven K, O'Donnell V, Tesfamichael S, Rudge P, Collinge J, Mead S. Development of novel clinical examination scales for the measurement of disease severity in Creutzfeldt-Jakob disease. J Neurol Neurosurg Psychiatry 2022:jnnp-2021-327722. [PMID: 35022318 DOI: 10.1136/jnnp-2021-327722] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
14 Kovanlikaya I, Chiang GC. Creutzfeldt-Jakob Disease. Hybrid PET/MR Neuroimaging 2022. [DOI: 10.1007/978-3-030-82367-2_33] [Reference Citation Analysis]
15 Eraña H, Charco JM, Pérez-castro MA, Díaz-domínguez CM, Sampedro-torres-quevedo C, Kortazar-zubizarreta I, Fernández-veiga L, Tasis-galarza J, Castilla J. Laboratory Identification of Prion Infections. Encyclopedia of Infection and Immunity 2022. [DOI: 10.1016/b978-0-12-818731-9.00131-2] [Reference Citation Analysis]
16 Demetriou E, Tachrount M, Ellis M, Linehan J, Brandner S, Collinge J, Mead S, Shmueli K, Farrow M, Golay X. Mapping prion pathology in mice using quantitative imaging: an MRI study.. [DOI: 10.1101/2021.12.28.474373] [Reference Citation Analysis]
17 Stevenson M, Uttley L, Oakley JE, Carroll C, Chick SE, Wong R. Interventions to reduce the risk of surgically transmitted Creutzfeldt-Jakob disease: a cost-effective modelling review. Health Technol Assess 2020;24:1-150. [PMID: 32122460 DOI: 10.3310/hta24110] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
18 Peden AH, Suleiman S, Barria MA. Understanding Intra-Species and Inter-Species Prion Conversion and Zoonotic Potential Using Protein Misfolding Cyclic Amplification. Front Aging Neurosci 2021;13:716452. [PMID: 34413769 DOI: 10.3389/fnagi.2021.716452] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
19 Wälzlein JH, Schwenke KA, Beekes M. Propagation of CJD Prions in Primary Murine Glia Cells Expressing Human PrPc. Pathogens 2021;10:1060. [PMID: 34451524 DOI: 10.3390/pathogens10081060] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
20 Arshad H, Patel Z, Mehrabian M, Bourkas MEC, Al-Azzawi ZAM, Schmitt-Ulms G, Watts JC. The aminoglycoside G418 hinders de novo prion infection in cultured cells. J Biol Chem 2021;297:101073. [PMID: 34390689 DOI: 10.1016/j.jbc.2021.101073] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Bergasa-Caceres F, Rabitz HA. Identification of Two Early Folding Stage Prion Non-Local Contacts Suggested to Serve as Key Steps in Directing the Final Fold to Be Either Native or Pathogenic. Int J Mol Sci 2021;22:8619. [PMID: 34445324 DOI: 10.3390/ijms22168619] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
22 Schwenke KA, Wälzlein J, Bauer A, Thomzig A, Beekes M. Primary glia cells from bank vole propagate multiple rodent-adapted scrapie prions.. [DOI: 10.1101/2021.08.06.455381] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
23 Zattoni M, Legname G. Tackling prion diseases: a review of the patent landscape. Expert Opin Ther Pat 2021;:1-19. [PMID: 34134584 DOI: 10.1080/13543776.2021.1945033] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
24 Chen C, Dong X. Therapeutic implications of prion diseases. Biosafety and Health 2021;3:92-100. [DOI: 10.1016/j.bsheal.2020.09.001] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
25 Ritchie DL, Barria MA. Prion Diseases: A Unique Transmissible Agent or a Model for Neurodegenerative Diseases? Biomolecules 2021;11:207. [PMID: 33540845 DOI: 10.3390/biom11020207] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
26 T. Foliaki S, R. Groveman B, L. Haigh C. Electrophysiological Investigations of Prion Protein Roles in Health and Disease. Neurodegenerative Diseases - Molecular Mechanisms and Current Therapeutic Approaches 2021. [DOI: 10.5772/intechopen.90049] [Reference Citation Analysis]
27 Shiraishi N, Hirano Y. Combination of Copper Ions and Nucleotide Generates Aggregates from Prion Protein Fragments in the N-Terminal Domain. Protein Pept Lett 2020;27:782-92. [PMID: 32096738 DOI: 10.2174/0929866527666200225124829] [Reference Citation Analysis]
28 Ishikawa T. Saccharomyces cerevisiae in neuroscience: how unicellular organism helps to better understand prion protein? Neural Regen Res 2021;16:489-95. [PMID: 32985470 DOI: 10.4103/1673-5374.293137] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
29 Nihat A, Mok TH, Odd H, Thompson A, Caine D, Mcniven K, O’donnell V, Tesfamichael S, Rudge P, Collinge J, Mead S. Development of novel clinical examination scales for the measurement of disease severity in Creutzfeldt-Jakob disease.. [DOI: 10.1101/2020.11.01.20224089] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
30 Arshad H, Bourkas MEC, Watts JC. The utility of bank voles for studying prion disease. Prog Mol Biol Transl Sci 2020;175:179-211. [PMID: 32958232 DOI: 10.1016/bs.pmbts.2020.08.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
31 Uttley L, Carroll C, Wong R, Hilton DA, Stevenson M. Creutzfeldt-Jakob disease: a systematic review of global incidence, prevalence, infectivity, and incubation. Lancet Infect Dis 2020;20:e2-e10. [PMID: 31876504 DOI: 10.1016/S1473-3099(19)30615-2] [Cited by in Crossref: 71] [Cited by in F6Publishing: 53] [Article Influence: 23.7] [Reference Citation Analysis]
32 Jang B, Kim M, Lee Y, Ishigami A, Kim Y, Choi E. Vimentin citrullination probed by a novel monoclonal antibody serves as a specific indicator for reactive astrocytes in neurodegeneration. Neuropathol Appl Neurobiol 2020;46:751-69. [DOI: 10.1111/nan.12620] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
33 Eraña H, Charco JM, González-Miranda E, García-Martínez S, López-Moreno R, Pérez-Castro MA, Díaz-Domínguez CM, García-Salvador A, Castilla J. Detection of Pathognomonic Biomarker PrPSc and the Contribution of Cell Free-Amplification Techniques to the Diagnosis of Prion Diseases. Biomolecules 2020;10:E469. [PMID: 32204429 DOI: 10.3390/biom10030469] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
34 Jaunmuktane Z, Brandner S. Invited Review: The role of prion-like mechanisms in neurodegenerative diseases. Neuropathol Appl Neurobiol 2020;46:522-45. [PMID: 31868945 DOI: 10.1111/nan.12592] [Cited by in Crossref: 48] [Cited by in F6Publishing: 53] [Article Influence: 16.0] [Reference Citation Analysis]
35 Krance SH, Luke R, Shenouda M, Israwi AR, Colpitts SJ, Darwish L, Strauss M, Watts JC. Cellular models for discovering prion disease therapeutics: Progress and challenges. J Neurochem 2020;153:150-72. [PMID: 31943194 DOI: 10.1111/jnc.14956] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
36 Nakagawa Y, Yamada S. Metal homeostasis disturbances in neurodegenerative disorders, with special emphasis on Creutzfeldt-Jakob disease - Potential pathogenetic mechanism and therapeutic implications. Pharmacol Ther 2020;207:107455. [PMID: 31863817 DOI: 10.1016/j.pharmthera.2019.107455] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
37 Bernardi L, Bruni AC. Mutations in Prion Protein Gene: Pathogenic Mechanisms in C-Terminal vs. N-Terminal Domain, a Review. Int J Mol Sci 2019;20:E3606. [PMID: 31340582 DOI: 10.3390/ijms20143606] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
38 Thackray AM, Andréoletti O, Bujdoso R. Mammalian prion propagation in PrP transgenic Drosophila. Brain 2018;141:2700-10. [PMID: 29985975 DOI: 10.1093/brain/awy183] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
39 Moda F, Bolognesi ML, Legname G. Novel screening approaches for human prion diseases drug discovery. Expert Opin Drug Discov 2019;14:983-93. [PMID: 31271065 DOI: 10.1080/17460441.2019.1637851] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
40 Vorberg I, Chiesa R. Experimental models to study prion disease pathogenesis and identify potential therapeutic compounds. Curr Opin Pharmacol 2019;44:28-38. [PMID: 30878006 DOI: 10.1016/j.coph.2019.02.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
41 Zafar S, Noor A, Zerr I. Therapies for prion diseases. Handb Clin Neurol 2019;165:47-58. [PMID: 31727228 DOI: 10.1016/B978-0-444-64012-3.00004-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
42 Jaunmuktane Z, Brandner S. Transmissible human proteopathies: an expanding field. Diagnostic Histopathology 2019;25:16-22. [DOI: 10.1016/j.mpdhp.2018.11.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
43 Relaño-Ginés A, Lehmann S, Brillaud E, Belondrade M, Casanova D, Hamela C, Vincent C, Poupeau S, Sarniguet J, Alvarez T, Arnaud JD, Maurel JC, Crozet C. Lithium as a disease-modifying agent for prion diseases. Transl Psychiatry 2018;8:163. [PMID: 30135493 DOI: 10.1038/s41398-018-0209-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
44 Kanata E, Thüne K, Xanthopoulos K, Ferrer I, Dafou D, Zerr I, Sklaviadis T, Llorens F. MicroRNA Alterations in the Brain and Body Fluids of Humans and Animal Prion Disease Models: Current Status and Perspectives. Front Aging Neurosci 2018;10:220. [PMID: 30083102 DOI: 10.3389/fnagi.2018.00220] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 3.4] [Reference Citation Analysis]
45 Thackray AM, Andréoletti O, Bujdoso R. The use of PrP transgenic Drosophila to replace and reduce vertebrate hosts in the bioassay of mammalian prion infectivity. F1000Res 2018;7:595. [PMID: 29946445 DOI: 10.12688/f1000research.14753.1] [Reference Citation Analysis]
46 Wolfe MS. Solving the Puzzle of Neurodegeneration. The Molecular and Cellular Basis of Neurodegenerative Diseases 2018. [DOI: 10.1016/b978-0-12-811304-2.00001-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
47 Roguski A, Gill AC. The Role of the Mammalian Prion Protein in the Control of Sleep. Pathogens 2017;6. [PMID: 29149024 DOI: 10.3390/pathogens6040058] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]